發炎標記市場規模、佔有率和成長分析：按標誌物類型、技術、應用、最終用戶、樣品類型和地區分類－2026-2033年產業預測

2024 年全球發炎標記市場價值為 62.8 億美元，預計到 2025 年將成長至 67.8 億美元，到 2033 年將成長至 124.5 億美元，在預測期（2026-2033 年）內複合年成長率為 7.9%。

全球發炎標記市場主要由診斷檢測、試劑盒和平台驅動，這些產品用於測量C反應蛋白、白細胞介素-6和腫瘤壞死因子-α等生物標記物，以評估疾病活動度。類風濕性關節炎、心血管疾病和感染疾病等慢性疾病的日益普遍凸顯了早期檢測的必要性，有助於改善治療決策和患者預後。隨著發炎標記物被納入個人化醫療和藥物研發，對高精度、高通量檢測的需求日益成長，這些檢測對於患者分層和監測治療反應至關重要。人工智慧驅動的自動化技術的進步正在革新發炎標記物的測量方式，最佳化檢測流程，提高結果可靠性，並簡化各種醫療機構的工作流程，從而加速先進多重檢測平台和分散式檢查方案的普及應用。

全球發炎標記市場按標誌類型、技術、應用、最終用戶、檢體類型和地區進行細分。依標記類型分類，市場細分包括C反應蛋白（CRP）、紅血球沉積速率（ESR）、抑鈣素（PCT）、白細胞介素和腫瘤壞死因子（TNF）。按技術分類，市場細分包括免疫檢測、酵素連結免疫吸附試驗（ELISA）、基於PCR的檢測法和多重檢測法。按應用分類，市場細分為自體免疫疾病、感染疾病、心血管疾病和腫瘤學。按最終用戶分類，市場細分為醫院、診斷檢查室和研究機構。依檢體類型分類，市場細分為血液、血清、血漿和其他生物體液。按地區分類，市場細分為北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。

全球發炎標記市場的成長要素

隨著醫療專業人員日益認知到發炎標記在疾病早期檢測、風險評估和治療效果監測中的關鍵作用，全球發炎標記市場正經歷顯著成長。人們對這些生物標記臨床應用的信心不斷增強，推動了對可靠檢測套組的需求，促使製造商拓展產品線並加大對教育計畫的投入。隨著臨床醫生將這些標記納入日常診療實踐，檢測需求日益成長，促使檢查室採用更先進的檢測平台。這些平台通常具有更高的靈敏度和更快的檢測結果報告速度，進一步促進了市場擴張，並隨著發炎標記物更廣泛地融入標準臨床方案，有助於改善患者管理效果。

全球發炎標記市場限制因素

全球發炎標記市場面臨許多挑戰，其中最主要的原因是先進檢測方法的高成本。這些方法通常需要複雜的設備、專用試劑和嚴格的品管，導致購置和營運成本居高不下。因此，許多醫療機構，尤其是預算有限的機構，可能會推遲投資或限制檢測數量，以有效控制成本。這種財務壓力阻礙了這些檢測方法的廣泛應用，對資金有限的小規模檢查室和新興市場造成了顯著影響。由此，市場滲透率低限制了臨床價值的認可，而財務障礙則進一步阻礙了研究機構提供更多檢測選擇，減緩了市場成長。

全球發炎標記市場趨勢

全球發炎標記市場正呈現出顯著的趨勢，即採用整合了細胞激素和趨化素評估以及急性期蛋白測量的多參數發炎檢測組合。這種轉變能夠實現更精準的疾病分層，尤其是在發炎訊號往往模糊不清的複雜病例中，從而支持個體化治療策略。這一趨勢的根本原因在於人們認知到，包括自體免疫疾病和心血管疾病在內的各種疾病的發炎路徑存在差異。同時，實驗室正透過自動化和先進的數據分析來簡化操作流程，從而提升了綜合生物標記分析的價值，並促進了全球診斷試劑生產商和醫療服務提供者之間就保險報銷問題展開廣泛的討論與合作。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球發炎標記市場規模：按標誌類型分類

• C反應蛋白（CRP）
• 紅血球沉積速率（ESR）
• 抑鈣素（PCT）
• 白細胞介素
• 腫瘤壞死因子（TNF）

全球發炎標記市場規模：按技術分類

• 免疫檢測
• ELISA
• 基於PCR的檢測
• 多重偵測

全球發炎標記市場規模：按應用領域分類

• 自體免疫疾病
• 感染疾病
• 心血管疾病
• 腫瘤學

全球發炎標記市場規模：按最終用戶分類

• 醫院
• 診斷檢查室
• 研究機構

全球發炎標記市場規模：按樣本類型分類

• 血
• 血清
• 電漿
• 其他生物體液

全球發炎標記市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Siemens Healthineers AG
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• bioMerieux SA
• QIAGEN NV
• Sysmex Corporation
• Beckman Coulter, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• QuidelOrtho Corporation
• Agilent Technologies, Inc.
• Randox Laboratories Ltd.
• DiaSorin SpA
• Trinity Biotech plc
• Sekisui Diagnostics
• Mindray Medical International Limited
• Shenzhen New Industries Biomedical Engineering Co., Ltd.
• PerkinElmer, Inc.

結論與建議

Global Inflammatory Marker Market size was valued at USD 6.28 Billion in 2024 and is poised to grow from USD 6.78 Billion in 2025 to USD 12.45 Billion by 2033, growing at a CAGR of 7.9% during the forecast period (2026-2033).

The global inflammatory marker market is primarily driven by diagnostic assays, kits, and platforms that measure biomarkers such as C-reactive protein, interleukin-6, and tumor necrosis factor-a to assess disease activity. The growing prevalence of chronic diseases, including rheumatoid arthritis, cardiovascular conditions, and infectious diseases, underscores the necessity for early detection, which enhances therapeutic decision-making and patient outcomes. The incorporation of inflammatory markers into personalized medicine and drug development intensifies the demand for precise, high-throughput assays essential for patient stratification and response monitoring. The rise of AI-driven automation is revolutionizing the measurement of inflammatory markers by optimizing laboratory processes, enhancing result reliability, and streamlining workflows across various healthcare settings, thereby facilitating advanced multiplex platforms and decentralized testing initiatives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Inflammatory Marker market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Inflammatory Marker Market Segments Analysis

The global inflammatory marker market is segmented by marker type, technology, application, end user, sample type and region. Based on marker type, the market is segmented into C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Procalcitonin (PCT), Interleukins and Tumor Necrosis Factor (TNF). Based on technology, the market is segmented into Immunoassay, ELISA, PCR-Based Assays and Multiplex Assays. Based on application, the market is segmented into Autoimmune Diseases, Infectious Diseases, Cardiovascular Diseases and Oncology. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories and Research Institutes. Based on sample type, the market is segmented into Blood, Serum, Plasma and Other Biological Fluids. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Inflammatory Marker Market

The Global Inflammatory Marker market is experiencing significant growth as healthcare providers increasingly recognize the critical role of inflammatory markers in early disease detection, risk assessment, and monitoring therapeutic efficacy. This growing confidence in the clinical application of these biomarkers is driving up demand for reliable testing kits, prompting manufacturers to diversify their product offerings and invest in educational initiatives. As clinicians integrate these markers into routine practice, the frequency of referrals increases, encouraging laboratories to adopt advanced platforms. These platforms typically offer enhanced sensitivity and expedited reporting, fueling the market's expansion and facilitating better patient management outcomes as inflammatory markers become more widely incorporated into standard clinical protocols.

Restraints in the Global Inflammatory Marker Market

The Global Inflammatory Marker market faces significant challenges due to the high costs associated with advanced testing methods. These methods often require intricate instruments, specialized reagents, and stringent quality controls, leading to elevated purchase and operational expenses. As a result, many healthcare facilities, especially those with constrained budgets, may delay investments or limit the number of tests conducted in order to manage costs effectively. This financial pressure hinders widespread adoption of these tests, particularly affecting smaller laboratories and emerging markets with limited funding. Consequently, the slow market penetration restricts the perceived clinical value, and financial obstacles also inhibit research institutions from expanding their assay offerings, further stunting market growth.

Market Trends of the Global Inflammatory Marker Market

The Global Inflammatory Marker market is witnessing a notable trend toward the adoption of multiplexed inflammatory panels that integrate cytokine and chemokine assessments alongside acute-phase protein measurements. This shift facilitates more refined disease stratification and supports personalized therapeutic strategies, particularly in complex cases where inflammatory signals may be ambiguous. The recognition that inflammatory pathways differ across various conditions, including autoimmune disorders and cardiovascular diseases, underpins this trend. Concurrently, laboratories are enhancing their operations through automation and advanced data analytics, which elevate the perceived value of comprehensive biomarker profiling and stimulate broader reimbursement discussions and collaborations between diagnostic manufacturers and healthcare providers worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Inflammatory Marker Market Size by Marker Type & CAGR (2026-2033)

• Market Overview
• C-Reactive Protein (CRP)
• Erythrocyte Sedimentation Rate (ESR)
• Procalcitonin (PCT)
• Interleukins
• Tumor Necrosis Factor (TNF)

Global Inflammatory Marker Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Immunoassay
• ELISA
• PCR-Based Assays
• Multiplex Assays

Global Inflammatory Marker Market Size by Application & CAGR (2026-2033)

• Market Overview
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Oncology

Global Inflammatory Marker Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Research Institutes

Global Inflammatory Marker Market Size by Sample Type & CAGR (2026-2033)

• Market Overview
• Blood
• Serum
• Plasma
• Other Biological Fluids

Global Inflammatory Marker Market Size & CAGR (2026-2033)

• North America (Marker Type, Technology, Application, End User, Sample Type)
  • US
  • Canada
• Europe (Marker Type, Technology, Application, End User, Sample Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Marker Type, Technology, Application, End User, Sample Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Marker Type, Technology, Application, End User, Sample Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Marker Type, Technology, Application, End User, Sample Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuidelOrtho Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trinity Biotech plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sekisui Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mindray Medical International Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shenzhen New Industries Biomedical Engineering Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations